3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
11
Sarcoma
1
CNS
1
Conditions
Respiratory Tract Diseases
1
Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Temozolomide
165
Magnetic Resonance Spectroscopy
130
Radiotherapy
95
Specimen Handling
80
Radiosurgery
60
Cyclophosphamide
55
pembrolizumab
51
Bevacizumab
51
Nivolumab
48
Radiation
47
Carboplatin
34
Biopsy
33
Irinotecan
29
Lomustine
25
Etoposide
25
Vincristine
23
Topotecan
23
Ipilimumab
23
dinutuximab
21
Cisplatin
21
Blood Specimen Collection
21
fludarabine
19
Radiotherapy, Intensity-Modulated
19
X-Rays
18
Surgical Procedures, Operative
18
abemaciclib
16
Mental Status and Dementia Tests
16
Granulocyte-Macrophage Colony-Stimulating Factor
16
Pemetrexed
15
atezolizumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gefitinib
×
CNS
×
1 year
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled